Healthcare >> CEO Interviews >> May 13, 2003
CHRIS MIRABELLI is General Partner, HealthCare Ventures, LLC. Dr.
Mirabelli has more than twenty years of experience in the
pharmaceutical and biotechnology industry, and in biomedical
research as both a Senior Executive and Scientist. Dr. Mirabelli
served as Chairman of the Board and Chief Executive Officer of
LeukoSite, Inc. from 1993 through 1999. Under his leadership,
LeukoSite became a premier company in the discovery and
development of therapeutics targeting white blood cell-mediated
diseases. The company raised more than $125MM in capital in
private, corporate and public financings, established corporate
R&D alliances with major pharmaceutical companies, and through
internal R&D and the acquisition of technology and other
companies, constructed a pipeline of multiple product
opportunities spanning late phase clinical development and early
research and drug discover. LeukoSite's success culminated in its
merger with Millennium Pharmaceuticals in December 1999. Dr.
Mirabelli presided over the integration of LeukoSite into
Millennium as President of Pharmaceutical R&D and a member of the
company's Board of Directors until mid-2000. Under Dr.
Mirabelli's direction, LeukoSite grew from a valuation of $16MM
at inception to near $1 billion upon completion of the merger.
Dr. Mirabelli was a founder of Isis Pharmaceuticals, Inc., where
he served as an Executive Vice President from 1992 to 1993,
Senior Vice President of Research from 1989 to 1991. He was
member of SmithKline and French Laboratories R&D Division from
1981 to 1988, where he held a number of positions including
Director of the Molecular Pharmacology Department. Dr. Mirabelli
received his Ph.D. degree in Molecular Pharmacology from Baylor
College of Medicine in Houston, Texas in 1981. He has authored
more than 191 scientific publications, abstracts and review
articles, and is an author on 18 issued patents. He joined HCV in
2000. Profile
Dr. Mirabelli: We're a venture capital group that focuses in the
area of the life sciences, in particular biopharmaceuticals and
biotechnology. We have
